Contraceptive choice affects consistency of use-temporarily

Article

Those who used contraceptive vaginal ring users during a 3-month period tended to report perfect use more often than oral contraceptive users, according to study findings published in March 2010 Obstetrics & Gynecology.

A 3-month study of contraceptive use among female college and graduate students found that those who used the contraceptive vaginal ring tended to report perfect use more often than those who used oral contraceptives. However, at 6-month follow-up, less than 30% of those enrolled continued to use their assigned method of birth control.

A total of 273 women were given either the vaginal ring or oral contraceptive pill and instructed to use it over a period of 3 consecutive menstrual cycles. Enrollees filled out online diaries daily to record whether they used the method that day and their satisfaction with the method of birth control during the cycles in which it was used.

At 3-month follow-up, 43% of 121 contraceptive vaginal ring users and 52% of 126 oral contraceptive users indicated they would still use that method (P=.16). At 6 months, just 26% of 117 vaginal ring users and 29% of oral contraceptive users had actually continued to use the designated method of contraception. Approximately 50% of each group reported either using condoms or nothing at all.

The study was published in Obstetrics & Gynecology (2010;115[3]:503-510).

Recent Videos
Empowering women to take charge of their health | Image Credit: © piecesofi.com - © piecesofi.com - stock.adobe.com.
Supporting women through menopause with knowledge and care | Image Credit: © SHOTPRIME STUDIO - © SHOTPRIME STUDIO - stock.adobe.com.
How fezolinetant revolutionizes non-hormonal menopause therapy | Image Credit: imsociety.org
Gulf War exposures linked to early menopause in women veterans | Image Credit: linkedin.com.
Vanessa Muñiz discusses benefits of clinical hypnosis against hot flashes | Image Credit: mindbodymedicine.artsandsciences.baylor.edu
Elinzanetant displays positive phase 3 safety and efficacy data against VMS | Image Credit: © toeytoey - © toeytoey - stock.adobe.com.
Lauren Streicher, MD
© 2024 MJH Life Sciences

All rights reserved.